BioWorld

Oct. 6, 2003

View Archived Issues

Cubist Signs Chiron As Ex-U.S. Partner For Cubicin Marketing

Ariad Gets $41M In Private Sale For Drug Development

Ligand Pulls Down $12.5M Through Royalty Agreement

Flamel Raises $62M Through Sale Of Its Common Shares

Receptor BioLogix Steering Lead Product Toward Gastric Cancer

Other News To Note

Asking For More Data, FDA Places Hold On DOV's Ocinaplon Phase III

The FDA placed a hold on DOV Pharmaceutical Inc.'s pivotal Phase III trial for an anti-anxiety candidate, asking for additional safety data. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for June 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 11, 2025.

3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

BioWorld

3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...

Corestemchemon preps US BLA filing for stem cell ALS therapy

BioWorld Asia

Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...

Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

BioWorld

With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...